This bill adds "multi-cancer early detection screening tests" to the Medicare benefit by amending section 1861 of the Social Security Act and creates a new payment and standards subsection in section 1834. It defines covered tests narrowly (FDA-cleared/approved tests that are genomic blood tests analyzing cell-free nucleic acids or comparable specimen-based tests), requires the Secretary to use the National Coverage Determination (NCD) process to assess reasonable and necessary use, and sets an initial payment rule pegged to the existing multi-target stool DNA test rate until 2031.
The statute also imposes utilization limits—a rising age threshold beginning at 68 in 2028 and an 11‑month interval between billable tests—and preserves a USPSTF override: if the U.S. Preventive Services Task Force assigns an A or B grade and coverage is provided under the relevant preventive coverage provision, the new payment rules do not apply. The measure matters to diagnostic manufacturers, clinical laboratories, providers, and Medicare administrators because it creates the first statutory pathway and specific reimbursement mechanics for multi-cancer early detection tests under Medicare FFS.
At a Glance
What It Does
The bill amends Medicare statute to add a defined category—multi-cancer early detection screening tests—and directs CMS to evaluate new tests through the NCD process. It establishes a temporary payment amount tied to the multi-target stool DNA test rate through 2030 and transitions to a payment determined under section 1834A beginning 2031, while also specifying utilization limits.
Who It Affects
Medicare fee-for-service beneficiaries within the specified age window, diagnostic manufacturers and labs developing FDA-cleared genomic blood-based multi-cancer tests, clinicians who order or interpret those tests, and CMS/Medicare contractors responsible for coverage and payment determinations.
Why It Matters
This is the first bill to put multi-cancer early detection screening explicitly into Medicare statute with concrete reimbursement mechanics, which will influence market adoption, test development pathways (FDA clearance/approval), and CMS administrative processes for coverage, coding, and claims adjudication.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a new, statutory category of "multi-cancer early detection screening tests" into the Medicare benefit and defines what counts. To qualify, a test must be furnished on or after January 1, 2028, and must have an FDA pathway—cleared under section 510(k), classified under 513(f)(2), or approved under 515—and be either a genomic sequencing blood (or blood product) test analyzing cell-free nucleic acids or a test using other biological material that CMS determines gives comparable results.
The Secretary must determine coverage using the National Coverage Determination process, not ad hoc local decisions.
On payment, the bill creates a new subsection in section 1834 specifying that, before January 1, 2031, Medicare's payment for these tests equals the payment amount already used for multi-target stool DNA tests; beginning January 1, 2031, payment is the lesser of that stool-DNA‑based amount or the rate determined under section 1834A. The statute also adds utilization controls: no payment if the beneficiary has reached the statutory age threshold for that year (68 in 2028, increasing by one year each subsequent year) as of January 1, or if the beneficiary had the same test in the prior 11 months.The bill includes a clear escape hatch tied to the U.S. Preventive Services Task Force: if a multi-cancer test receives a USPSTF A or B recommendation and coverage follows under the preventive coverage provision referenced in the bill, then the special payment and limitation rules do not apply.
Finally, a standalone rule of construction clarifies that this new coverage does not supplant existing Medicare coverage for established single-cancer screening tests (breast, cervical, colorectal, lung, prostate) and does not prevent those tests from being used diagnostically in conjunction with other screening results.
The Five Things You Need to Know
The bill sets January 1, 2028 as the earliest date tests may be furnished and still qualify as a covered multi-cancer early detection screening test.
To qualify, a test must have an FDA pathway: 510(k) clearance, classification under 513(f)(2), or PMA approval under 515—the bill excludes non‑FDA cleared tests from the statutory definition.
Medicare will pay for qualifying tests through a new section 1834(aa) that pegs payment before 2031 to the multi-target stool DNA test payment amount and, starting 2031, caps payment at the lesser of that stool-DNA amount or the rate set under section 1834A.
The bill prohibits payment if, as of January 1 of the year, the beneficiary has reached a statutory age threshold (68 in 2028, increasing by 1 year annually) or if the same test was provided within the previous 11 months.
If the USPSTF assigns an A or B recommendation and CMS provides coverage under the referenced preventive coverage provision, the bill’s special payment and limitation rules do not apply (the USPSTF recommendation supersedes this subsection’s payment regime).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Names the measure as the "Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act." This is purely formal but signals congressional intent to treat multi-cancer screening as a discrete Medicare benefit to be handled by statute rather than solely administrative guidance.
New benefit category and statutory definition
Amends section 1861 to add "multi-cancer early detection screening tests" to the list of covered items and creates a detailed statutory definition at new subsection (nnn). The definition requires an FDA clearance/approval pathway (510(k), 513(f)(2) classification, or 515 approval), limits covered technologies to genomic sequencing blood tests analyzing cell-free nucleic acids or CMS-determined equivalents, sets January 1, 2028 as the earliest furnishing date, and directs the Secretary to use the National Coverage Determination (NCD) process to decide whether a specific test is "reasonable and necessary." Practically, manufacturers will need an explicit FDA pathway for their product to be considered under Medicare’s statutory category, and CMS must treat coverage questions through the formal NCD channel.
Payment amount, timing, and utilization limits
Adds a new payment subsection specifying that, until January 1, 2031, Medicare will pay for covered multi-cancer tests at the same dollar amount used for multi-target stool DNA tests; on or after January 1, 2031, payment is the lesser of that amount or the rate determined under section 1834A. The subsection also creates two utilization controls: (1) an age-based eligibility cutoff that starts at 68 in 2028 and increases by one year annually, assessed as of January 1 each year; and (2) an 11-month minimum interval between reimbursable tests. These mechanics create a time-limited, administratively simple pricing rule up front, while leaving longer-term payment methodology to section 1834A or future CMS action.
USPSTF override for high‑value preventive recommendations
States that if a multi-cancer early detection test receives a USPSTF A or B grade and CMS provides coverage under the referenced preventive coverage provision, the new payment and limitation rules in the added subsection do not apply. In other words, a favorable USPSTF recommendation moves the test into the standard preventive-coverage stream, bypassing the temporary payment regime and utilization caps in the new subsection.
Technical fixes and preservation of existing screening coverage
Makes conforming edits in sections 1833 and 1862 to incorporate the new subsection of 1834 into existing payment and exclusion language, adds a new exclusion under 1862(a) clarifying when tests are not reasonable and necessary, and includes a rule of construction explicitly stating that this legislation does not affect Medicare coverage for existing single-cancer screening tests or prevent those tests from being used diagnostically in conjunction with other screenings. These changes are administrative but important: they integrate the new category into current claims-payment rules and attempt to avoid statutory conflicts with existing screening benefits.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries in the eligible age window — will gain potential access to FDA-cleared multi-cancer blood-based screening tests under fee-for-service Medicare, which could increase early detection opportunities for multiple cancer types.
- Diagnostic manufacturers and clinical laboratories with FDA-cleared genomic multi-cancer tests — receive a statutory coverage pathway and a defined interim payment rate, reducing reimbursement uncertainty and creating a clearer commercial pathway.
- Clinicians who order preventive testing — gain an explicit Medicare coverage category to justify offering or recommending multi-cancer screening to eligible patients and to rely on a defined claims/payment framework for billing.
Who Bears the Cost
- The Medicare program (CMS/Trust Fund) — assumes financial exposure for a new screening category with an initial payment benchmark that could drive utilization and downstream diagnostic costs (imaging, biopsies, follow-up care).
- Manufacturers and labs working with tests that lack FDA clearance/approval — face an effective exclusion from this statutory pathway, increasing regulatory and commercial costs if they must pursue FDA pathways to qualify.
- CMS and contractors (NCD process administrators and MACs) — bear administrative burden to adjudicate NCDs, implement new coding and payment instructions, and manage annual age thresholds and utilization edits.
Key Issues
The Core Tension
The bill tries to accelerate beneficiary access to promising multi-cancer screening technologies while constraining cost and clinical uncertainty through strict definitional, payment, and utilization rules; that balance pits the desire to encourage innovation and early detection against the risk of paying for tests whose net clinical benefit, downstream costs, and optimal use patterns are still evolving.
The bill centers coverage on FDA-cleared or approved tests and on CMS’s NCD process, which narrows the pathway to Medicare to technologies that follow particular regulatory tracks. This creates a sharp distinction between tests with formal FDA market authorization and those developed or offered as laboratory-developed tests (LDTs) without such authorization; the latter appear excluded unless CMS later determines comparability.
The reliance on the NCD process also means coverage may be delayed while CMS completes evidentiary review, even after a test has FDA clearance.
Payment mechanics present trade-offs. Pegging early payment to the multi-target stool DNA rate provides a quick administrative anchor but may be an imperfect comparator for complex genomic blood tests; it could either overpay for tests with limited downstream value or underpay for more expensive, higher-complexity assays.
The age-based, annually increasing cutoff starting at 68 creates a narrow early-beneficiary cohort and may delay access for younger Medicare enrollees; the statutory 11-month interval is administrable but arbitrary relative to evolving clinical guidance on appropriate screening frequency. Finally, the USPSTF escape valve creates two coverage regimes—statutory interim payment rules versus established preventive coverage—that could generate short-term market and clinical behavior distortions depending on how and when the USPSTF acts.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.